The diagnostic gray zone between Burkitt lymphoma and diffuse large B-cell lymphoma is also a gray zone of the mutational spectrum

Leukemia

Volumn 29, Issue 8, 2015, Pages 1789-1791

  Momose, S ^a,b   Weissbach S ^a,b   Pischimarov, J ^a,b   Nedeva, T ^a,b   Bach, E ^a   Rudelius, M ^a,b   Geissinger, E ^a,b   Staiger, A M ^c   Ott, G ^c   Rosenwald, A ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b Comprehensive Cancer Center Mainfranken ^*  (Germany)

^c ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INHIBITOR OF DIFFERENTIATION 3; PROTEIN BCL 2; TRANSCRIPTION FACTOR 7 LIKE 1; TRANSCRIPTION FACTOR EZH2; TUMOR MARKER;

BURKITT LYMPHOMA; CCND3 GENE; GENE; GENE MUTATION; GENE TRANSLOCATION; HUMAN; LARGE CELL LYMPHOMA; LETTER; MUTATION RATE; ONCOGENE MYC; PRIORITY JOURNAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; PROGNOSIS;

BURKITT LYMPHOMA; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MUTATION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84938954876     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2015.34     Document Type: Letter

References (15)

1. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.
2. Horn H, Ziepert M, Becher C, Barth TF, Bernd HW, Feller AC et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013; 121: 2253-2263.
3. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R et al. The genetic landscape of mutations in Burkitt lymphoma. Nat Genet 2012; 44: 1321-1325.
4. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. Nat Genet 2012; 44: 1316-1320.
5. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature 2012; 490: 116-120.
6. Bodor C, O'Riain C, Wrench D, Matthews J, Iyengar S, Tayyib H et al. EZH2 Y641 mutations in follicular lymphoma. Leukemia 2011; 25: 726-729.
7. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. Proc Natl Acad Sci USA 2012; 109: 3879-3884.
8. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010; 42: 181-185.
9. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011; 476: 298-303.
10. Pasqualucci L, Trifonov V, Fabbri G, Ma J, Rossi D, Chiarenza A et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet 2011; 43: 830-837.
11. Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA 2013; 110: 1398-1403.
12. Gebauer N, Bernard V, Feller AC, Merz H. ID3 mutations are recurrent events in double-hit B-cell lymphomas. Anticancer Res 2013; 33: 4771-4778.
13. Robbiani DF, Nussenzweig MC. Chromosome translocation, B cell lymphoma, and activation-induced cytidine deaminase. Annu Rev Pathol 2013; 8: 79-103.
14. Ryan RJ, Nitta M, Borger D, Zukerberg LR, Ferry JA, Harris NL et al. EZH2 codon 641 mutations are common in BCL2-rearranged germinal center B cell lymphomas. PLoS One 2011; 6: e28585.
15. Vaidya R, Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R (X)CHOP era. Ann Oncol 2014; 25: 2124-2133.